Citadel Advisors’s Jupiter Neurosciences JUNS Stock Holding History

Citadel Advisors’s Portfolio JUNS Stock Details JUNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,355	Closed	-$38.2K	–	15178
2026 Q1	$38.2K	Buy	+1,355	New	+$62.5K	﹤0.01%	12507

Other funds holding JUNS

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return

Citadel Advisors's JUNS Position: Q2 2026 in Review

Citadel Advisors sold out of Jupiter Neurosciences (JUNS) in Q2 2026, closing a stake of 1,355 shares — an estimated $38.2K sold.

Citadel Advisors first reported a position in JUNS in Q1 2026 and held it in 1 quarter. The position peaked at $38.2K in Q1 2026. 13 funds tracked by Wall St. Rank hold JUNS as of Q2 2026.

Citadel Advisors reported no remaining Jupiter Neurosciences position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 1,355 Jupiter Neurosciences shares in Q2 2026, an estimated $38.2K.
Citadel Advisors first reported a position in Jupiter Neurosciences in Q1 2026 and held it in 1 quarter.
Citadel Advisors's Jupiter Neurosciences position peaked at $38.2K in Q1 2026.
13 funds tracked by Wall St. Rank held Jupiter Neurosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.